LAUSR

Background : Current guidelines recommend bronchodilators (Beta2-agonists, Anticholinergics, Methylxanthines) in stable COPD, which do not possess direct anti-inflammatory properties. At the same time, the efficacy of drugs that diminish the inflammation of bronchial mucosa (Fenspirid) remains the matter of discussion. Aim : To study the efficacy of treatment of stable COPD with Fenspiride. Material and methods : The study included 42 patients (mean age 49.3±2.8 years) with stable COPD with GOLD stage I and II, divided into 2 groups, comparable by age, sex, duration and stage of the disease and duration of smoking. Patients in group 1 (n=20), administered Fenspiride (Eurespal, Les Lab. Servier Ind. - France) 80 mg 2 times a day for 6 months on the background of treatment with bronchodilators (Beta2-agonists). Patients in group 2 (n=22), received for 6 months only treatment with bronchodilators (Beta2-agonists). Results : The treatment of patients during 6 months improved bronchial permeability in both groups. In group 1, FEV1 grew by 14.9% (p Conclusion : Fenspiride administered as a long-term treatment is an effective additional remedy to improve COPD symptoms.